Acute Myeloid Leukemia
BMS Acquires Orum’s ADC ORM-6151 for AML and MDS Treatment
Bristol Myers Squibb (BMS) has made a significant move in the field of antibody-drug conjugates (ADCs) by acquiring Orum Therapeutics’ ...
Syros slashes workforce and appoints new CEO amid partnership losses
Syros Pharmaceuticals is undergoing a significant transformation, which includes a workforce reduction of 35%, as it narrows its focus to ...
Magrolimab fails to improve survival in leukemia, Gilead halts trial
Another failure has occurred in Gilead Sciences’ $4.9 billion immuno-oncology wager. Following an ad hoc analysis of a phase 3 ...
Quizartinib Gets Green Light in EU for Treating Acute Myeloid Leukemia
Daiichi Sankyo has received a positive recommendation for the approval of quizartinib in the European Union (EU). This recommendation is ...
Gilead’s Magrolimab Faces Fresh Setback as FDA Issues Partial Clinical Hold
One month after Gilead Sciences made public its decision to halt a myelodysplastic syndromes (MDS) program centered around magrolimab, the ...
Gilteritinib and Allo HSCT Together Increase Survival in FLT3-Mutated AML
Results from a real-world study presented at the European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting indicate ...
Ziftomenib: A Promising New Treatment for NPM1-Mutated Acute Myeloid Leukemia
Kura Oncology’s recent presentation at the European Hematology Association (EHA) 2023 conference highlighted the impressive clinical potential of ziftomenib in ...
Clinical Activity is Induced by Ziftomenib in NPM1-mutant R/R AML
Source – Kura Oncology Phase I data from the KOMET-001 trial (NCT04067336) showed that treatment with Ziftomenib, a menin-MLL (KMT2A) ...
Kura makes a $100 million offer when AML is caused by a Menin inhibitor
Source – Kura Oncology Safety problems had previously slowed down the development of Kura Oncology’s Menin inhibitor Ziftomenib for acute ...
Trial of 2seventy Bio’s AML cell treatment was put on hold following a death
Source – 2seventy bio On June 14, 2023, as a result of Seattle Children’s Therapeutics pausing a clinical study of ...
Kura Oncology Unveils Promising Clinical Results of Ziftomenib, at the 2023 European Hematology Association (EHA) Congress
Source – Kura Oncology Kura Oncology presented updated clinical data for its menin inhibitor, ziftomenib, at the 2023 European Hematology ...
